Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

was developed by Shire to give patients more choice in how they take their phosphate binder. Submissions for national marketing authorisations of FOSRENOL in oral powder form have been made to Sweden and the other 27 European markets, with the first national approvals anticipated in Q2 2012.

Pipeline


REPLAGAL - for the treatment of Fabry disease

  • On March 14, 2012 Shire announced that it had withdrawn its Biologics License Application ("BLA") for REPLAGAL with the FDA. In 2009, and again in 2011, the FDA encouraged Shire to submit an application for the approval of REPLAGAL in the US. These discussions led Shire to file a BLA in November 2011 in anticipation of a quick review process and eventual approval. Recent interactions with the FDA in Q1 2012 led Shire to believe that the FDA would require additional controlled trials for approval. No concerns over the product's safety profile were raised by the FDA. Shire has concluded that the likely additional studies would cause a significant delay, and an approval of REPLAGAL for US patients would only be possible in the distant future. Shire therefore decided to withdraw its BLA. Patients currently treated with REPLAGAL in the US under treatment access programs will be transitioned off REPLAGAL therapy by June 30, 2012.

SPD476, MMX® mesalamine - for the treatment of diverticular disease

  • On March 30, 2012 Shire announced top-line results of the PREVENT2 trial, a Phase 3 investigational study of once-daily SPD476, MMX mesalamine in patients with a history of diverticulitis. The study did not meet the primary endpoint in reducing the rate of recurrence of diverticulitis over a two year treatment period. Shire will continue to analyze these data and those of the second study, PREVENT1, which was similar in design to PREVENT2 and will report later in the year. Although the
    '/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
(Date:7/31/2014)... Calif. , July 31, 2014  Cepheid (NASDAQ: ... speaking at the following conferences, and invited investors to participate ... Access Conference, New York, NY Wednesday, ... Baird Health Care Conference, New York, NY ... Time , Accessing Live Webcasts To access the ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6Xencor Reports Second Quarter 2014 Financial Results 7Xencor Reports Second Quarter 2014 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... 31, 2014 United Theological Seminary will ... on Monday, September 15, with its 2014 Opening Convocation, ... 3440 Shroyer Rd., Kettering, OH. Dr. Emma J. Justes, ... Emma Toussant Chair will speak on “Unexpected Undercurrents: Responding ... teaching and research interests include pastoral care and counseling, ...
(Date:7/31/2014)... 31, 2014 Dr. Stewart Shofner ... the first surgeons in the United States to successfully treat ... the smallest medical device ever approved by the FDA. ... recognize the benefits of using a procedure known as Selective ... Shofner and his colleagues now recognize that this procedure is ...
(Date:7/31/2014)... Las Vegas, NV (PRWEB) July 31, 2014 ... marketing expert Adam Short that is designed to provide a ... has caught the attention of Shane Michaels, prompting an investigative ... here . , “What really speaks volumes about the success ... the tactics and strategies included in it have stayed effective ...
(Date:7/31/2014)... Cosmetic Town has introduced a secure verification ... will be able to verify their patients before the ... guarantees their authenticity. This will help prospective patients ... information that has been verified to come from a ... Town to filter out fake patients who leave fraudulent ...
Breaking Medicine News(10 mins):Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:United Theological Seminary to Open 144th Year 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 2Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 3Health News:Nashville’s Top Eye Surgeon, Dr. Stewart Shofner Successfully Treats Glaucoma Patients Using a Procedure Known as Selective Laser Trabeculoplasty (SLT) 4Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Cosmetic Town Improves Patient Experience Through Secure Verification of Patients and Doctors 2
... RICHMOND, Va., April 29 The principal U.S. investigator,for ... for,malpractice in his use of the device by a ... No. 07-206, Circuit Court, City of Richmond, Va., ... H.,Mathews, M.D., and Midatlantic Spine Specialists, P.C. Dr. Mathews ...
... 1950 had agreement on standard outcomes, review finds , , ... the appropriate measurements for assessing drug clinical trials that ... 9,000 pediatric clinical trials conducted since 1950. , They ... none have involved children in the process to select ...
... PITTSBURGH, April 29 Mylan Inc. (NYSE: MYL ... approval,from the U.S. Food and Drug Administration (FDA) for ... mg, 2 mg and 4 mg., Trandolapril Tablets ... and generic versions of this product had total U.S.,sales ...
... A New LTCI Presentation System Designed for Today,s ... LLC, the leader in,providing long-term care insurance sales, ... announced the release of,simplifyingLTC, a LTCI presentation system ... presentation system communicates the risk of long-term care ...
... More than 50,000 doctors,have given 20 million free ... to Reach Out and Read. Partnering with doctors ... to their parents at check-ups, Reach,Out and Read ... toddlers,and preschoolers. The children,s literacy program recently reached ...
... Growth of 27-29 Percent over ... 2007 First-Quarter Year-Over-Year Highlights (adjusted for January 2008 ... two-for-one stock split): - GAAP ... from $0.52, excluding $0.05 in amortization of intangible assets ...
Cached Medicine News:Health News:Virginia Judge Rules Medical Device Pioneer Committed Malpractice 2Health News:Measurements Poor for Assessing Clinical Trials With Children 2Health News:SellingLTC.com Develops simplifyingLTC 2Health News:20 Million Kids' Books Distributed, 25% of U.S. Children in Poverty Getting Books, 50,000 Doctors Trained: Three Key Milestones for Reach Out and Read 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 2Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 3Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 4Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 5Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 6Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 7Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 8Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 9Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 10Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 11Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 12Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 13Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 14Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 15Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 16Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 17Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 18Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 19Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 20Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 21Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 22Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 23Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 24Health News:Medco Reports Strong First-Quarter Results; Record EPS, Mail-Order Volume, Generic Dispensing Rates 25
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... musculofascial tract, renal capsule, and parenchyma during ... the catheter shaft. Radiopaque markers are placed ... the balloon. The radiopaque dilator/sheath assembly is ... coaxial placement of the sheath. Supplied sterile ...
... Therapy for Urinary Control offers a ... and the symptoms of overactive bladder, ... symptoms of urgency-frequency alone or in ... or could not tolerate more conservative ...
... Receiving timely, high-quality and accurate,ECG ... care. The,Quinton Eclipse Premier allows ... test results,and make a diagnosis ... sharing capabilities.,Workload is further streamlined ...
Medicine Products: